Pacific Biosciences of California Director Acquires $603,538 in Stock (PACB)
Pacific Biosciences of California (NASDAQ:PACB) Director William W. Ericson bought 123,423 shares of the stock on the open market in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $4.89 per share, for a total transaction of $603,538.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Pacific Biosciences of California (NASDAQ:PACB) traded down 1.16% on Monday, hitting $5.12. The stock had a trading volume of 55,881 shares. Pacific Biosciences of California has a 52 week low of $3.32 and a 52 week high of $8.20. The stock has a 50-day moving average of $5.30 and a 200-day moving average of $5.52. The company’s market cap is $361.6 million.
Pacific Biosciences of California (NASDAQ:PACB) last posted its quarterly earnings results on Thursday, July 24th. The company reported ($0.27) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.15) by $0.12. The company had revenue of $11.40 million for the quarter, compared to the consensus estimate of $11.39 million. During the same quarter in the prior year, the company posted ($0.33) earnings per share. The company’s quarterly revenue was up 90.0% on a year-over-year basis. Analysts expect that Pacific Biosciences of California will post $-1.07 EPS for the current fiscal year.
Pacific Biosciences, Inc develops Deoxyribonucleic Acid (NASDAQ:PACB) sequencing platform.
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with Analyst Ratings Network's FREE daily email newsletter.